Form 4 for YARW Yarrow Bioscience, Inc.
Accepted 2022-03-18 00:00:00 ET · period of report 2022-03-17 · accession 0001209191-22-020067 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-18 | 2022-03-17 | YARW | Zeronda Tyler | CFO | A - Grant | $0.00 | +75.0K | 162.3K | +86% | $0 |
| D | 2022-03-18 | 2022-03-17 | YARW | Zeronda Tyler | CFO | A - Grant | $0.00 | +75.0K | 75.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-17 | A | A | 75,000 | $0.00 | 162,329 | D | — | — | (F1) Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc. |
| 2 | Derivative | Stock Options | 2022-03-17 | A | A | 75,000 | $0.00 | 75,000 | D | $0.61 · — to 2032-03-17 | 75,000 Common Stock | (F2) The awards vest over four years, 25% on March 31, 2023 and 6.25% every three months thereafter, ending on March 31, 2026. |